Anxiety Depression, Schizophrenia and Related Disorders
Conditions
Keywords
Schizophrenia, Antipsychotics, Aripiprazole, Brexpiprazole
Brief summary
MainRexult study aims to carefully evaluate a cohort of patients with schizophrenia and related disorder prescribed with the combination therapy with Abilify Maintena and Rexulti on its efficacy and tolerability in a real-life clinical setting.
Detailed description
Currently, there is no recommendation on next-step treatment strategy if the patients remain suffering from residual symptoms, have incomplete remission, or have acute exacerbation of schizophrenia whilst receiving aripiprazole long acting injection at its recommended (maximum) dose, except to switch to other second generation antipsychotics (SGA) or to clozapine if they are in their treatment-resistant course. Such practice may incur risks of full relapse and/or unnecessary side effects to the patients, in particularly to those already showed insufficient treatment response, intolerability to side effects, or non-adherence to other antipsychotics before. On the contrary, adding another SGAs to this special cohort appears to be rational. Especially, brexpiprazole might be an ideal choice for its serotonin-dopamine activity modulator property to achieve better symptom control, and at the same time retaining the benefits from the lower incidence of side effects than other SGAs. Cases reports on combination therapy with aripiprazole (oral or LAI) with brexpiprazole had demonstrated initial favorable outcomes, albeit lacking empirical evidence from randomized controlled trial or longer term follow-up study. Therefore, the current MainRexult study aims to carefully evaluate a cohort of patients with schizophrenia and related disorders prescribed with the combination therapy with Abilify Maintena and Rexulti on its efficacy and tolerability in an non-interventional, naturalistic real-life clinical setting.
Interventions
DRUGARIPiprazole Injection [Abilify]
subject already receiving the combination of Abilify Maintena and Rexulti
DRUGBrexpiprazole
subject already receiving the combination of Abilify Maintena and Rexulti
Sponsors
The University of Hong Kong
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Inclusion criteria
* Age: 18- 65 years old at the time of enrollment * Able to read and communicate in English and/or Chinese * Able to give informed consent * Has been diagnosed to have Schizophrenia (DSM-5 or ICD-10 F20 \[except F20.81\], Schizotypal (Personality) Disorder (DSM-5 or ICD-10 F21), or Schizoaffective Disorder (DSM-5 or ICD-10 F25), (Persistent) Delusional Disorder (DSM-5 or ICD-10 F22), Schizophreniform Disorder (DSM-5 or ICD-10 F20.81), Brief Psychotic Disorder (DSM-5) or Acute and Transient Psychotic Disorder (ICD-10 F23) * Is receiving the combination with Abilify Maintena and brexpiprazole as treatment ≤8 weeks at the time of recruitment
Exclusion criteria
* Age \<18 years old * Unable to read English or Chinese * Unable to give informed consent * Had been diagnosed to have Intellectual Disabilities (DSM-5) or Mental Retardation (ICD-10 F70-73)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline score of the Brief Psychiatric Rating Scale-24 at 3rd and 6th months | 6 months | Measuring efficacy on positive and negative psychotic symptoms with a total score ranges from 24 (normal) to 168 (severe ill) |
| Change from baseline score of the Clinical Global Impression Scale at 3rd and 6th months | 6 months | measuring efficacy on overall clinical improvement and severity of subjects with a score ranges from 0 (normal) to 18 (severely ill) |
| Change from baseline score of the Hamilton Anxiety Rating Scale at 3rd and 6th months | 6 months | measuring anxiety symptoms of the subjects with a score ranges from 0 (not ill) to 56 (severe) |
| Change from basline score of the Hamilton Depression Rating Scale at 3rd and 6th months | 6 months | measuring depressive symptoms of the subjects with a score ranges from 0 (normal) to 62 (very severe) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from basline score of the Simpson Angus Score at 3rd and 6th months | 6 months | for intolerability assessment on extra-pyramidal side effects of the subjects from 0 (not present) to 24 (most severe) |
| Change from baseline score of the Barnes Akathisia Rating Scale at 3rd and 6th months | 6 months | for intolerability assessment on akathisia of the subjects from 0 (not present) to 14 (severe) |
Countries
Hong Kong
Contacts
PRINCIPAL_INVESTIGATORAlbert KK Chung
The University of Hong Kong
Outcome results
None listed